Navigation Links
Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

Fourth Quarter 2008 Highlights:

-- Revenue of $99.7 million, up 23.6% year-over-year or up 30.9% on a constant currency basis

-- Net income of $11.3 million or $0.32 per diluted share, compared to a net loss of $5.4 million in fourth quarter 2007

Full Year 2008 Highlights:

-- Revenue of $423.4 million, up 45.5% year-over-year or up 46.4% on a constant currency basis

-- Net income of $24.0 million or $0.68 per diluted share, compared to a net loss of $0.1 million in 2007

WARSAW, Ind., Feb. 24 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopedic device industry and other medical markets, announced today fourth quarter and full year 2008 financial results for the period ended January 3, 2009.


                               Fourth Quarter            Full Year
    (in millions,
    except share data)     2008    2007  Change    2008   2007   Change

    Revenue                $99.7   $80.7   24%   $423.4   $290.9   46%
    Operating Income         9.5    3.6   166%     42.0     13.1  221%
    Net Income              11.3   (5.4)  311%     24.0     (0.1) Fav
    EPS (Diluted)          $0.32 $(0.16)  300%    $0.68       $-  Fav

    Revenue by Product:
    Instruments            $44.4  $28.5    56%   $177.5    $79.1  124%
    Implants                29.6   23.2    27%    122.6     96.9   27%
    Cases                   18.5   19.2    -3%     86.4     77.2   12%
    Other                    7.2    9.8   -27%     36.9     37.8   -2%
        Total Revenue      $99.7  $80.7    24%   $423.4   $290.9   46%

Revenue for the fourth quarter 2008 was $99.7 million, up 23.6% or up 30.9% assuming foreign exchange rates in 2008 consistent with those experienced in 2007 ("a constant currency basis") from $80.7 million reported in the fourth quarter 2007. Fourth quarter 2008 revenue included an incremental $12.9 million from the Company's New Bedford, Massachusetts manufacturing facility, which was acquired from DePuy Orthopaedics, Inc. in January 2008. Excluding this acquisition, the Company achieved organic revenue growth of 7.7% or 15.0% on a constant currency basis over the fourth quarter of 2007.

Gross profit for the fourth quarter 2008 was $23.3 million, an increase of 57.4% from $14.8 million for the fourth quarter 2007. Gross margin percentage for the fourth quarter 2008 was 23.4% compared to a gross margin percentage of 18.4% in the same period last year and 22.9% in the third quarter 2008. Excluding the Sheffield, UK operating unit, gross margin was 26.2% in the fourth quarter 2008 and 27.4% in the third quarter 2008.

Selling, general and administrative expenses were $13.9 million for the fourth quarter 2008, compared to $11.3 million in the fourth quarter 2007. The two primary drivers for the year-over-year increase include non-cash stock based compensation and the addition of the New Bedford facility which was acquired in January 2008.

Operating income for the fourth quarter of 2008 was $9.5 million compared to $3.6 million for the fourth quarter 2007. Operating margin for the fourth quarter 2008 was 9.5%, an increase from 4.4% for the fourth quarter 2007.

Net income for the fourth quarter 2008 was $11.3 million, or $0.32 per diluted share, compared to a net loss of $5.4 million, or $(0.16) per diluted share, for the fourth quarter of 2007. The net impact of various tax items on the fourth quarter 2008 results was $6.9 million or $0.20 per diluted share, made up of income tax benefits primarily from the realization of losses on the Company's initial investment in the Sheffield, UK operations partially offset by additional tax provisions for uncertain tax positions worth $8.7 million. Fourth quarter net income was also adversely impacted by the provision of $1.8 million for tax valuation allowances associated with the Company's UK operations.

2008 full year revenue was $423.4 million, a 45.5% increase or a 46.4% increase on a constant currency basis over the full year 2007. The Company achieved organic revenue growth of 23.4% or 24.3% on a constant currency basis over the full year 2007. Gross margin percentage for the full year 2008 was 23.7% compared to 18.1% for 2007. Excluding the Sheffield operations, full year 2008 gross margin was 28.2%. Net income for the full year 2008 was $24.0 million, or $0.68 per diluted share, compared to a net loss of $0.1 million for the full year 2007. The net impact of the various tax items on the full year results was a favorable $5.0 million or $0.14 per diluted share, made up of income tax benefits primarily from the realization of losses on the Company's initial investment in the Sheffield, UK operations partially offset by additional tax provisions for uncertain tax positions worth $8.0 million. Full year net income was also adversely impacted by the provision of $3.0 million for tax valuation allowances associated with the Company's UK operations. Also impacting 2008 results is approximately $5.0 million non-recurring professional fees related to the Sheffield investigation.

The weighted average number of diluted shares outstanding during the fourth quarter of 2008 was 35,368,601.

Brian Moore, President and Chief Executive Officer of Symmetry Medical, stated, "Fourth quarter results reflect the continuing strength of our business and position in the orthopedic industry, with revenue up 31% on a constant currency basis from 2007. Our bottom line was impacted by the favorable tax initiative that will have significant cash benefits.

"We are encouraged by the continuing improvement at our Sheffield, UK facility, the performance of our New Bedford facility which was well above expectations and the continued development of our Malaysia facility."

Mr. Moore continued, "Looking forward into 2009, we have an optimistic outlook on the many opportunities that our strong market position offers. However, given the current macroeconomic climate, we are managing the business on a conservative basis as we gauge the extent and breadth of the impact on the orthopedic arena."

Financial Guidance

The following forward-looking estimates regarding 2009 earnings guidance are based on current market conditions and foreign currency comparisons. Actual results may differ materially, and we refer you to forward-looking statements located at the end of the press release.

For the full year 2009, the Company expects revenue to be in the range of $405 million to $420 million. On a constant currency basis, we expect a revenue increase of 2%-6% for the full year. The Company currently expects full year 2009 earnings per diluted share in the range of $0.75 to $0.85. With regard to the Company's Sheffield, UK unit, the Company expects to incur smaller net operating losses during the first half 2009 prior to reaching operating profitability in the second half of 2009.

AAOS

Symmetry Medical will be participating in the American Academy of Orthopedic Surgeons (AAOS) 2009 Annual Meeting in Las Vegas, NV, February 25 - March 1, 2009. Symmetry Medical products and technologies will be located at Booth 2659.

Conference Call

Symmetry Medical will host a conference all at 9:00 a.m. ET on February 24, 2009. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate website at www.symmetrymedical.com. The dial-in numbers are (866) 713-8566 for domestic callers and (617) 597-5325 for international. The reservation number for both is 36114752. After the live Web cast, the call will remain available on Symmetry Medical's Web site through May 24, 2009. In addition, a telephonic replay of the call will be available until March 3, 2009. The replay numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 50628687.

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Forward-Looking Statements

Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking-Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at www.sec.gov.

    Investors/Media:
    The Ruth Group
    Nick Laudico/Jason Rando
    646-536-7030/7025
    nlaudico@theruthgroup.com
    jrando@theruthgroup.com

    Contact:
    Symmetry Medical Inc.
    Fred Hite
    Senior Vice President
    Chief Financial Officer
    (574) 371-2218

    Symmetry Medical Inc.
    Consolidated Statements of Operations

                             Three Months Ended        Twelve Months Ended
                           January 3,  December 29,  January 3,  December 29,
                              2009          2007        2009          2007
                                  (In Thousands, Except Per Share Data)
                           (unaudited)   (unaudited)
    Revenue                  $99,662       $80,662    $423,406      $290,922
    Cost of Revenue           76,315        65,825     323,048       238,343

    Gross Profit              23,347        14,837     100,358        52,579
    Selling, general,
     and administrative
     expenses                 13,866        11,274      58,340        39,484

    Operating Income           9,481         3,563      42,018        13,095
    Other (income) expense:
    Interest expense           1,792         1,909      10,092         6,917
    Derivatives valuation
     (gain)/ loss             (1,419)       (1,100)     (2,460)        1,740
    Other                        293         5,768       2,874          (503)

    Income before
     income taxes              8,815        (3,014)     31,512         4,941
    Income tax expense        (2,502)        2,359       7,493         5,090

    Net income               $11,317       $(5,373)    $24,019         $(149)

    Net income per share:
    Basic                      $0.32        $(0.16)      $0.68            $-
    Diluted                    $0.32        $(0.16)      $0.68            $-


    Weighted average common
     shares and equivalent
     shares outstanding:
    Basic                     35,196        35,134      35,170        35,089
    Diluted                   35,369        35,306      35,357        35,268



    Symmetry Medical Inc.
    Consolidated Balance Sheets

                                                  January 3,   December 29,
                                                     2009          2007

                                                      (In Thousands)
    Assets:
    Current Assets:
    Cash and cash equivalents                     $10,191       $12,089
    Accounts receivable, net                       52,845        42,992
    Inventories                                    61,111        45,353
    Refundable income taxes                         6,610         6,516
    Deferred income taxes                           3,993         2,551
    Derivative valuation asset                          -             2
    Other current assets                            3,154         2,940

    Total current assets                          137,904       112,443
    Property and equipment, net                   115,045       100,424
    Goodwill                                      153,521       141,985
    Intangible assets, net of accumulated
     amortization                                  45,039        44,567
    Other assets                                    1,728         1,011

    Total Assets                                 $453,237      $400,430

    Liabilities and Shareholders' Equity:
    Current Liabilities:
    Accounts payable                              $26,929       $34,518
    Accrued wages and benefits                     12,784        10,922
    Other accrued expenses                          5,186         8,096
    Income tax payable                              2,637         2,394
    Derivative valuation liability                      -            74
    Deferred income taxes                               -           407
    Revolving line of credit                        2,495         6,511
    Current portion of capital lease
     obligations                                    1,034         2,487
    Current portion of long-term debt              16,900        10,900

    Total current liabilities                      67,965        76,309
    Deferred income taxes                          18,131        12,136
    Derivative valuation liability                  3,771         1,917
    Capital lease obligations, less current
     portion                                        3,356         4,032
    Long-term debt, less current portion          107,600        68,500

    Total Liabilities                             200,823       162,894

    Commitments and contingencies (Note 15)

    Shareholders' Equity:
    Common Stock, $.0001 par value; 72,410
     shares authorized; shares issued January
     3, 2009--35,801; December 29, 2007--
     35,444; December 30, 2006--35,107)                 4             4
    Additional paid-in capital                    275,890       272,623
    Accumulated deficit                           (21,507)      (45,526)
    Accumulated other comprehensive income         (1,973)       10,435

    Total Shareholders' Equity                    252,414       237,536

    Total Liabilities and Shareholders'
     Equity                                      $453,237      $400,430


'/>"/>
SOURCE Symmetry Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Symmetry Medical to Present at Canaccord Adams Musculoskeletal Conference
2. Symmetry Medical to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009
3. Symmetry Medical to Present at 20th Annual Piper Jaffray Healthcare Conference
4. Symmetry Medical Reports Third Quarter 2008 Financial Results
5. Symmetry Medical to Report Third Quarter 2008 Financial Results on November 12, 2008
6. Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million
7. Symmetry Medical to Report Second Quarter 2008 Financial Results on August 6, 2008
8. Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million
9. Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008
10. Symmetry Medical Reports Full Year 2007 Financial Results
11. Symmetry Medical Delays 10-K Filing to Complete Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Mammal Prize has officially been won. A team from 21st Century Medicine (21CM) ... a way to preserve the delicate neural circuits of an intact rabbit brain ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates ... they are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, ... be enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a full ... beneficiary of their ongoing community enrichment program. The current campaign fundraises for Angels ... are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Respiratory ... Summary GlobalData,s Medical Devices sector report, " ... " provides an overview of Respiratory Devices currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... NEW YORK , Feb. 8, 2016 /PRNewswire/ ... market, today announces its first male sexual enhancement ... enhancement, EnduramenT combines proven ethnobotanicals with a patented ... of nitric oxide, the chemical compound responsible for ... Forgoing the ...
Breaking Medicine Technology: